Progen's distribution arm picks up new agencies

By Pete Young
Wednesday, 03 April, 2002

Brisbane-based biotech Progen Industries has been appointed exclusive Australian distributor for two product ranges used by lab researchers.

Progen will distribute Pierce and Endogen brands through its life sciences division, which distributes biological and chemical research products in Australia and New Zealand.

The agreeement should help finance the main thrust of Progen's business which is centered around R&D activity related to its lead anti-cancer drug candidate PI-88 now in clinical trials.

Progen's life sciences division forms part of its commercial services unit, which last financial year generated more than $2.4 million and has already posted a 46 per cent rise in revenues this year. The unit also contract-manufactures potential therapeutics and vaccines under Good Manufacturing Standards (GMP).

Pierce products are used by researchers in protein chemistry, immunology and molecular biology. Endogen is a major supplier of compounds related to the measurement of cytokines and chemokines (the chemical messengers of the immune system).

Related News

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd